Clinical Report: Comprehensive Genomic Analysis Reveals MLPH in Prostate Cancer

Overview

This study identifies MLPH as a candidate susceptibility gene for prostate cancer (PCa) through integrative genomic analysis.

Background

Prostate cancer is a prevalent malignancy with significant genetic complexity. Understanding the genetic factors contributing to PCa susceptibility is crucial for improving risk stratification and therapeutic strategies. This study aims to elucidate the genetic underpinnings of PCa by integrating multi-omics data.

Data Highlights

Key Findings

• Identified 23 consensus candidate genes linked to PCa susceptibility.
• MLPH was prioritized based on tumor-context cis-eQTL analysis in TCGA-PRAD.
• MLPH expression was upregulated in PCa tissues compared to normal tissues.
• Lower MLPH expression correlated with higher preoperative PSA levels.
• MLPH expression was associated with histological differentiation in tumors.

Clinical Implications

Further investigation is warranted to explore the role of MLPH in prostate cancer.

Conclusion

MLPH emerges as a significant candidate gene in prostate cancer.

Related Resources & Content

1. npj Digital Medicine, 2025 -- Combining Single-Cell and Spatial Transcriptomics with Explainable AI Uncovers Critical Prognostic Factors in Prostate Cancer
2. Evaluation of Clinical Risk Assessment Tools and Predictive Models for Detecting Pathogenic Germline Variants in Advanced Prostate Cancer Patients, 2023
3. The ASCO Post, 2022 -- Polygenic Score May Enable More Precise PSA Screening for Prostate Cancer
4. A secreted biomarker profile differentiates between indolent and aggressive prostate cancer types, 2025
5. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1 | Journal of Clinical Oncology
6. Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer | New England Journal of Medicine
7. Exploring the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with homologous recombination repair alteration: a meta-analysis based on subgroups and reconstructed individual patient data - PMC
8. Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1 | Journal of Clinical Oncology
9. Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer | New England Journal of Medicine
10. Exploring the efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with homologous recombination repair alteration: a meta-analysis based on subgroups and reconstructed individual patient data - PMC